These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 12483367

  • 21. [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
    Tabata S, Ohno T, Tomo K, Hishita T, Hada S, Mizumoto T, Furukawa H.
    Rinsho Ketsueki; 2003 May; 44(5):313-7. PubMed ID: 12822405
    [Abstract] [Full Text] [Related]

  • 22. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S, Umeki K, Hayashi T, Fukutsuka K, Okumura A, Kishimori C.
    Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 26. Autografting in chronic myeloid leukemia.
    Carella AM, Beltrami G, Corsetti MT.
    Semin Hematol; 2003 Jan; 40(1):72-8. PubMed ID: 12563613
    [Abstract] [Full Text] [Related]

  • 27. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA.
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [Abstract] [Full Text] [Related]

  • 28. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW.
    Haematologica; 2004 Jan; 89(1):49-57. PubMed ID: 14754606
    [Abstract] [Full Text] [Related]

  • 29. Autologous stem cell transplantation in chronic myeloid leukemia.
    Olavarria E.
    Semin Hematol; 2007 Oct; 44(4):252-8. PubMed ID: 17961724
    [Abstract] [Full Text] [Related]

  • 30. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou SY, Zhou AP, Zhang CG, Ai B.
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [Abstract] [Full Text] [Related]

  • 31. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ, Li JL, Zhu HH, Ruan GR, Li LD, Zhang Y, Xu LP, Liu DH, Liu YR, Huang XJ, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [Abstract] [Full Text] [Related]

  • 32. Difficulties in collecting peripheral blood stem cells in chronic myeloid leukemia related to persistence of the leukemic cell clone.
    Hénon PR, Eisenmann JC, Becker M, Beck-Wirth G, Wunder E, Sovalat H.
    Stem Cells; 1993 Oct; 11 Suppl 3():43-7. PubMed ID: 8298478
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C.
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 May 15; 12(10):3037-42. PubMed ID: 16707599
    [Abstract] [Full Text] [Related]

  • 37. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M, Rybicki L, Pohlman B, Sobecks R, Andresen S, Kuczkowski E, Bolwell B.
    J Clin Oncol; 2006 Aug 01; 24(22):3604-10. PubMed ID: 16877727
    [Abstract] [Full Text] [Related]

  • 38. PBPC mobilization with chemotherapy and G-CSF in patients with chronic myeloid leukemia: quantification of bcr/abl-positive cells by interphase fluorescence in situ hybridization and competitive PCR.
    Keil F, Mitterbauer G, Chen X, Haas OA, Kalhs P, Lechner K, Mannhalter C, Moser K, Worel N, Pirc-Danoewinata H, Louda N, Loidolt H, Rabitsch W, Greinix HT.
    Transfusion; 2001 Jan 01; 41(1):111-6. PubMed ID: 11161255
    [Abstract] [Full Text] [Related]

  • 39. Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
    Salar A, Sureda A, Menéndez B, Sierra J.
    Haematologica; 2000 Mar 01; 85(3):326-7. PubMed ID: 10702830
    [No Abstract] [Full Text] [Related]

  • 40. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar 01; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.